US2012046242A1PendingUtilityA1
Molecular activators of the wnt/beta-catenin pathway
Est. expiryDec 24, 2028(~2.4 yrs left)· nominal 20-yr term from priority
A61K 31/55A61K 31/366A61K 31/201A61K 31/5575A61K 31/506A61K 31/4439A61K 31/52A61K 31/565A61K 31/421A61K 31/708A61K 31/27A61K 31/4152A61K 31/69A61K 31/4402A61K 31/407A61P 35/00A61K 31/166A61K 31/426A61K 31/351A61K 31/5383A61K 31/24A61K 31/4409A61K 31/15A61K 31/167A61K 31/405A61K 31/472A61K 31/403A61K 31/585A61K 31/404A61K 31/353A61K 31/365A61K 31/4245A61K 31/336A61K 31/047A61K 31/357A61K 31/695A61K 31/57A61K 31/553A61K 31/495A61K 31/5377A61K 31/7048A61K 31/4406A61K 31/4178A61K 31/196A61K 31/015A61K 31/352A61K 31/35
63
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present invention is directed toward a method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling by selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1, Table 2, and a pharmaceutically acceptable salt thereof. A method of similarly modulating the Wnt/β-catenin pathway in a subject is also discussed.
Claims
exact text as granted — not AI-modified1 . A method of treating a subject for a condition mediated by aberrant Wnt/β-catenin signaling, said method comprising:
selecting a subject with a condition mediated by aberrant Wnt/β-catenin signaling and administering to the selected subject a compound selected from the group consisting of those set forth in Table 1 or Table 2, and a pharmaceutically acceptable salt thereof.
2 . The method of claim 1 , wherein the subject is human.
3 . The method of claim 1 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered.
4 . The method of claim 1 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered.
5 . (canceled)
6 . A method of activating the Wnt/β-catenin pathway in a subject comprising:
selecting a subject in need of Wnt/β-catenin pathway activating and
administering to the selected subject a compound selected from the group consisting of those set forth in Table 1 or Table 2, and a pharmaceutically acceptable salt thereof.
7 . The method of claim 6 , wherein a compound of Table 1 or a pharmaceutically acceptable salt thereof is administered.
8 . The method of claim 6 , wherein a compound of Table 2 or a pharmaceutically acceptable salt thereof is administered.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.